`

Dewpoint Therapeutics

Biotechnology Research

Specialities :
Biomolecular condensates
Oncology
Neurodegeneration
Cardiopulmonary
Virology

+2

revenue-icon Revenue
11M - 100M
funding-icon Total Funding
$150.0M
size-icon Size
51 - 200

Frequently Asked Questions About Dewpoint Therapeutics

What does Dewpoint therapeutics do?+

Dewpoint is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Merck, and Pfizer. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable

What are Dewpoint therapeutics's specialties? +

Biomolecular condensates,oncology,neurodegeneration,cardiopulmonary,virology,insulin resistance,and rare disease

What is Dewpoint therapeutics's industry? +

Dewpoint therapeutics operates in the Biotechnology research industry.

What is Dewpoint therapeutics's revenue? +

Dewpoint therapeutics's revenue is 11m - 100m

What is Dewpoint therapeutics's company size? +

Dewpoint therapeutics has 51 - 200 employees.

The Go-to Sales Technology According to G2

G2 Badges Map
Get Started With Clodura
Sign Up

Sign Up for Free

Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.

Supercharge Your Prospecting

Supercharge Your Prospecting

Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.

Grow Your Business

Grow Your Business

Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.